Prior to founding Eccogene, Dr. Zhou was the head of chemistry at Lilly China R&D Center, where he led project teams to achieve candidate selection milestones for diabetes and diabetic complications. Before joining Lilly in 2012, Dr. Zhou was investigator at GlaxoSmithKline working on drug discovery campaigns utilizing disruptive DEL technology. Dr. Zhou began his career at Tetraphase pharmaceutical, where he co-invented Eravacycline, an FDA approved drug for cIAI. He holds a Ph.D. in chemistry from Brandeis University and received a B.S. in life science from Fudan University.
Had more than 20 years of R&D experience in metabolic diseases, with in depth understanding of metabolic diseases and crosstalk between metabolic and immune systems. He had his academic training in Fudan University, Salk Institute and UCSD, demonstrated involvement of intrinsic signaling and inflammation in the development of diabetes and fatty liver disease. During his work in Eli Lilly, he had led team to deliver multiple milestones from target validation to clinical development. Dr. Zhou and Dr. Xu founded Eccogene in 2018, focusing on drug discovery for metabolic and immune related diseases.
Dr. Jianfeng Xu, M.D. and Ph.D. in Biochemistry, was a former Global Clinical Development Manager in GSK before joining Eccogene. Dr. Xu has more than 20 years of experience in biomedical research and drug development. He was an attending physician specialized in neurology in Fujian Medical University First Affiliated Hospital for many years after graduating from Shanghai Medical (now Fudan) University Medical School. He then became a WHO Fellow in UCSF, a postdoctoral fellow and subsequently an Instructor in Harvard Medical School before joining Biogen Idec and later GSK as scientists working on drug discovery. In the past +10 years in GSK, he focused on global clinical drug development working on strategic planning, project management and clinical trial operations for phase I-IV trials in multiple therapeutic areas including neurological, metabolic, and infectious diseases.